Valion Bio (VBIO) Accumulated Expenses (2021 - 2025)

Valion Bio has reported Accumulated Expenses for 5 years, with the latest figure at $194000.0 in Q2 2025.

• On a quarterly basis, Accumulated Expenses rose 177.14% year-over-year to $194000.0 in Q2 2025; TTM through Jun 2025 was $194000.0, a 177.14% increase from a year earlier, with the FY2023 full-year figure at $218000.0, up 50.34% from the prior year.
• Accumulated Expenses was $194000.0 for Q2 2025 at Valion Bio, up from $40000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $218000.0 in Q4 2023, with the low at $40000.0 in Q3 2024.
• Average Accumulated Expenses over 5 years is $139000.0, with a median of $145000.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses slipped 29.61% in 2022, then surged 177.14% in 2025.
• Over 5 years, Accumulated Expenses stood at $206000.0 in 2021, then retreated by 29.61% to $145000.0 in 2022, then soared by 50.34% to $218000.0 in 2023, then sank by 81.65% to $40000.0 in 2024, then soared by 385.0% to $194000.0 in 2025.
• The last three Accumulated Expenses figures came in at $194000.0 (Q2 2025), $40000.0 (Q3 2024), and $70000.0 (Q2 2024), per Business Quant data.